{"downloaded": true, "htmlmade": false, "full": {"id": "29610115", "source": "MED", "pmid": "29610115", "pmcid": "PMC5894261", "fullTextIdList": {"fullTextId": "PMC5894261"}, "doi": "10.1182/bloodadvances.2017015263", "title": "A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.", "authorString": "Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, Cheson BD.", "authorList": {"author": [{"fullName": "Ujjani C", "firstName": "Chaitra", "lastName": "Ujjani", "initials": "C", "authorId": {"@type": "ORCID", "#text": "0000-0003-2662-4826"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC."}}}, {"fullName": "Wang H", "firstName": "Hongkun", "lastName": "Wang", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC."}}}, {"fullName": "Skarbnik A", "firstName": "Alan", "lastName": "Skarbnik", "initials": "A", "authorId": {"@type": "ORCID", "#text": "0000-0002-1276-7546"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and."}}}, {"fullName": "Trivedi N", "firstName": "Neel", "lastName": "Trivedi", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC."}}}, {"fullName": "Ramzi P", "firstName": "Pari", "lastName": "Ramzi", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC."}}}, {"fullName": "Khan N", "firstName": "Nadia", "lastName": "Khan", "initials": "N", "authorId": {"@type": "ORCID", "#text": "0000-0001-8259-4129"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fox Chase Comprehensive Cancer Center, Philadelphia, PA."}}}, {"fullName": "Cheson BD", "firstName": "Bruce D", "lastName": "Cheson", "initials": "BD", "authorId": {"@type": "ORCID", "#text": "0000-0001-9255-7655"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-8259-4129"}, {"@type": "ORCID", "#text": "0000-0001-9255-7655"}, {"@type": "ORCID", "#text": "0000-0002-1276-7546"}, {"@type": "ORCID", "#text": "0000-0003-2662-4826"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "7", "volume": "2", "journalIssueId": "2665802", "dateOfPublication": "2018 Apr", "monthOfPublication": "4", "yearOfPublication": "2018", "printPublicationDate": "2018-04-01", "journal": {"title": "Blood advances", "ISOAbbreviation": "Blood Adv", "medlineAbbreviation": "Blood Adv", "NLMid": "101698425", "ISSN": "2473-9529", "ESSN": "2473-9537"}}, "pubYear": "2018", "pageInfo": "762-768", "abstractText": "Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory setting. Based on these data, we conducted a phase 1 study of rituximab (R), lenalidomide (L), and ibrutinib (I) in relapsed/refractory CLL. Patients received R 375 mg/m<sup>2</sup> cycles 1 to 6 day 1, L on cycles 1 to 12 days 1 to 21, and I until disease progression. Dose escalation used a standard 3+3 design from a dose level (DL) of L 5 mg (DL1) and increasing to 15 mg (DL3) for a total of 3 dose levels. Twelve patients were enrolled; there were 2 dose-limiting toxicities of grade 4 neutropenia at DL3; thus, DL2 was the recommended phase 2 dose. A high incidence of sustained grade 4 neutropenia occurred at all dose levels, prompting study withdrawal in 5 patients, despite growth factor support. The ORR was 67%; ORR at the RP2D was 100% (1 CR). The 12-month progression-free survival at the RP2D was 83%. Preliminary efficacy data with the triplet did not appear superior to prior reports of the rituximab-lenalidomide doublet or single-agent ibrutinib. Given these findings and the sustained neutropenia, this regimen was not pursued. The study was registered at www.clinicaltrials.gov as #NCT02200848.", "affiliation": "Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": {"grantId": "P30 CA051008", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Neutropenia", "meshQualifierList": {"meshQualifier": {"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Pyrazoles", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Pyrimidines", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Salvage Therapy", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Drug Administration Schedule"}, {"majorTopic_YN": "N", "descriptorName": "Maximum Tolerated Dose"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Lymphocytic, Chronic, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CO", "qualifierName": "complications", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Rituximab", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Progression-Free Survival"}]}, "chemicalList": {"chemical": [{"name": "Pyrimidines", "registryNumber": "0"}, {"name": "Pyrazoles", "registryNumber": "0"}, {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}, {"name": "Rituximab", "registryNumber": "4F4X42SYQ6"}, {"name": "ibrutinib", "registryNumber": "1X70OSD4VX"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017015263"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5894261"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5894261?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017015263"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "8", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-02-19", "dateOfCreation": "2018-04-04", "firstIndexDate": "2018-04-04", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2020-12-21", "firstPublicationDate": "2018-04-01"}, "abstract": "Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory setting. Based on these data, we conducted a phase 1 study of rituximab (R), lenalidomide (L), and ibrutinib (I) in relapsed/refractory CLL. Patients received R 375 mg/m<sup>2</sup> cycles 1 to 6 day 1, L on cycles 1 to 12 days 1 to 21, and I until disease progression. Dose escalation used a standard 3+3 design from a dose level (DL) of L 5 mg (DL1) and increasing to 15 mg (DL3) for a total of 3 dose levels. Twelve patients were enrolled; there were 2 dose-limiting toxicities of grade 4 neutropenia at DL3; thus, DL2 was the recommended phase 2 dose. A high incidence of sustained grade 4 neutropenia occurred at all dose levels, prompting study withdrawal in 5 patients, despite growth factor support. The ORR was 67%; ORR at the RP2D was 100% (1 CR). The 12-month progression-free survival at the RP2D was 83%. Preliminary efficacy data with the triplet did not appear superior to prior reports of the rituximab-lenalidomide doublet or single-agent ibrutinib. Given these findings and the sustained neutropenia, this regimen was not pursued. The study was registered at www.clinicaltrials.gov as #NCT02200848.", "journaltitle": "Blood advances", "authorinfo": ["Ujjani C", "Wang H", "Skarbnik A", "Trivedi N", "Ramzi P", "Khan N", "Cheson BD"], "title": "A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL."}